BURLINGTON, N.C.—Increasingly, life-sciences companies and others in the life-sciences field have worked toward methods of more heavily personalizing patient monitoring and care through diagnostics, as a way of better understanding when intervention is needed and how a patient is responding to treatment. It’s an important aspect of personalized medicine efforts, as well as a help to many clinical trial efforts.
On the clinical care side of that, LabCorp and the New Jersey Primary Care Association (NJPCA), which represents 23 community health centers throughout New Jersey, recently announced the development of a database and information exchange platform supporting participating NJPCA health centers. The project will help NJPCA members achieve value-based care objectives by providing integrated lab and clinical data in a more accessible, comprehensive and secure manner, with a focus on improving outcomes for patients with chronic conditions, such as diabetes and chronic kidney disease.
LabCorp will make the the platform available through its Care Intelligence application, allowing for population health analyses across communities, as well as for enhanced monitoring of individual patients.
“NJPCA is excited about this partnership and looks forward to leveraging data to improve the delivery of care to New Jersey’s uninsured, underinsured and medically underserved populations,” said Jillian Hudspeth, president and CEO of the association. “A more holistic view of our patient population will drive operational performance and improve costs, patient outcomes, quality reporting and care coordination. Longer term, it will help our Community Health Centers establish the infrastructure to advance value-based care.”
“This partnership with NJPCA and HealthEC aligns well with LabCorp’s mission to improve health and improve lives,” added William B. Haas, senior vice president of LabCorp Diagnostics’ Northeast Division. “Laboratory test results influence up to 70 percent of clinical decisions. By combining lab and clinical data in one platform, this project will provide community health centers with a more comprehensive view of patient status. This comprehensive view will help them develop best practices and strategies to more readily identify at-risk patients and enhance care management programs, which are key components of the continuing move towards value-based care.”
Last month, LabCorp also announced that its Covance Drug Development business celebrated the opening of its new research and development center in Shanghai, which is now its largest facility in the Asia Pacific region.
“We entered China in 1998 and have grown our breadth of services, scientific capabilities and therapeutic expertise progressively, building our operations to meet global standards and requirements,” commented John Ratliff, currently CEO of Covance. “Today, we are the only provider to offer comprehensive R&D services from early development through commercial solutions in China, as well as globally. Our Shanghai R&D Center continues our investment in China, bringing professionals and teams together to serve both the burgeoning Chinese pharmaceutical and biotech industry, as well as global biopharmaceutical clients working in the region. I’m proud to dedicate this new facility on behalf of all our colleagues in China, who apply their talents and passion to develop solutions for our customers and for the patients who benefit from our mission to improve health and improve lives.”
And speaking of Ratliff, he will become CEO of LabCorp Diagnostics on Nov. 1. At the same time, Dr. Paul Kirchgraber, currently senior vice president and head of Covance’s clinical trial testing solutions, will succeed Ratliff as CEO of Covance.
“John has demonstrated his transformational leadership of the Covance business and has been deeply engaged with our LabCorp Diagnostics business over the past three years,” said Adam H. Schechter, who will take over as president and CEO of LabCorp on the same day. “As a long-tenured executive at Covance, Paul heads one of its most successful divisions and is ready to lead the business into the future. I look forward to working with John and Paul.”
“John and Paul are exceptional leaders who will continue working to fully realize the power of our unique capabilities in diagnostics and drug development,” noted David P. King, who is retiring as LabCorp president and CEO to become executive chairman of the board of directors. “Under Adam’s leadership and with their support, LabCorp is well positioned to grow and thrive in the years ahead as we pursue our noble mission to improve health and improve lives.”